ARTICLE SUMMARY:
Even as much of the medical device industry is preoccupied with transitional M&A and scale, compelling and not altogether contrarian pressures are favoring a move toward spin-outs.
Almost exactly a year ago, Baxter International Inc. announced it would split its medical devices and biosciences/ pharmaceutical businesses into two publicly traded companies, with the medical device assets remaining within Baxter and the biopharma assets going to spin-off Baxalta.
